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ABSTRACT The adamantanes are a class of compounds that have found use in the treatment of inﬂuenza A and Parkinson’s
disease, among others. The mode of action for inﬂuenza A is based on the adamantanes’ interaction with the transmembrane M2
channel,whereas the treatment ofParkinson’s disease is thought to relate to achannel block ofN-methyl-D-aspartate receptors. An
understanding of how these compounds interact with the lipid bilayer is thus of great interest. We used molecular-dynamics
simulations to calculate the potential of mean force of adamantanes in a lipid bilayer. Our results demonstrate a preference for the
interfacial region of the lipid bilayer for both protonated and deprotonated species, with the protonated species proving signiﬁcantly
more favorable. However, the protonated species have a large free-energy barrier in the center of themembrane. In contrast, there
is no barrier (compared with aqueous solution) at the center of the bilayer for deprotonated species, suggesting that the permeant
species is indeed the neutral form, as commonly assumed.We discuss the results with respect to proposedmechanisms of action
and implications for drug-delivery in general.
INTRODUCTION
Adamantane (tricyclo-decane) derivatives are a series of
compounds (Fig. 1) widely used in the treatment of various
diseases, including inﬂuenza (1) and Parkinson’s disease (2).
Amantadine (1-aminoadamantane) is perhaps the most
widely studied adamantane derivative. It is one of the oldest
compounds known to have an antiviral effect against inﬂu-
enza A (1,3–5), and was ﬁrst approved by the Food and Drug
Administration in 1966 (www.fda.gov). Since then, the re-
lated compound rimantadine has also been approved. The
antiviral action of both compounds is thought to arise from
inhibition of the M2 channel, a viroporin of inﬂuenza A (5).
Amantadine was also suggested to inhibit another viroporin,
the p7 protein of hepatitis C virus (HCV) (6). However, more
recent work suggested that amantadine had no effect on p7
ion-channel activity or the infectivity of HCV particles (7).
Nevertheless, amantadine was used in clinical trials to treat
HCV (8). Some of these trials reported success (9–12), but
controversy persists about the effectiveness of amantadine in
the clinic (13–17).
Amantadine and memantine (18) (Fig. 1) have also been
used in the treatment of Parkinson’s disease (19–21), with a
block of the N-methyl-D-aspartic acid (NMDA) receptors as
the most likely mode of action (22–24). However, according
to other reports, amantadine interacts with nicotinic acetyl-
choline receptors (23), raising the possibility of neuronal
nicotinic acetylcholine receptors as drug targets in the treat-
ment of Parkinson’s disease (25). Memantine is also thought
to target NMDA receptors in the treatment of Alzheimer’s
disease (26), and was recently used in the treatment of glau-
coma (27).
Amantadine and related compounds were shown to stabi-
lize clathrin-coated vesicles and lipid membranes, suggesting
a possible role in inhibition of ligand uptake (28,29). In addi-
tion, it was suggested that the therapeutic activity of aman-
tadine is related to nonspeciﬁc interactions (28–30).
Thus, adamantane derivatives appear to have many possi-
ble roles as therapeutic agents. At themolecular level, though,
the action of amantadine against the inﬂuenza A M2 channel
has received themost attention (1). The single transmembrane
domain of each M2 protein consists of an a-helix, and a
minimum of four of these is required to make a functional
channel that conducts protons. The most obvious mode of
action for amantadine is simply to sit inside the helical bundle
and thus block the pore (31). Indeed, twomutations that result
in resistance to amantadine occur on residues that are thought
to line the pore (A30T and G34E) (4). However, this ‘‘cork in
the bottle’’ mechanism is not easily reconciled with some of
the electrophysiological observations (32), or with results
obtained from amantadine-resistantmutants (33), and thus the
precise mode of action of amantadine remains controversial.
Hu et al. speculated that amantadine action might not in-
volve a simple block, but that interference with the His-37
residues facilitates proton conductance (34). Fluorescence
spectroscopy and circular dichroism experiments also suggest
a subtle change in the structure of the M2 channel in the
presence of amantadine (35). The location of amantadine-
resistant mutants suggests that amantadine resides in the ex-
ternalmembrane leaﬂet. Furthermore, amantadineonly inhibits
channel activity when it is applied to the medium that bathes
the N-terminal ectodomain (10 mM is enough), and not
when applied to the C-terminal tail (even in the presence of
1 mM) (36). More recently, both an x-ray structure and an
NMR structure of M2 in complex with amantadine (37)
and rimantadine (38), respectively, were described. Interest-
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ingly, two different modes of interaction were reported. The
amantadine structure supported the channel-block hypothe-
sis, whereas the rimantadine structure suggested an interac-
tion with the exterior of the M2 channel. Solid-state NMR
experiments implied that amantadine can alter the confor-
mational equilibrium of theM2 channel, and that amantadine-
resistant mutations create changes in this equilibrium that
result in altered binding properties (39).
Whatever the precise mode of interaction, it seems likely
that lipophilic compounds such as amantadine may reach the
channel after ﬁrst partitioning into the membrane. If one
additionally considers the role of adamantanes in the treat-
ment of neurodegenerative disorders, then permeation across
the membrane becomes an important consideration with re-
spect to the blood-brain barrier and pharmacokinetics (40).
Neutron and x-ray diffraction studies using 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC) showed that the ma-
jority of amantadine interacts with the lipid headgroups close
to the surface of membrane, whereas a minor proportion
penetrates deeper into the bilayer (41). Recent experiments
suggest that amantadine is signiﬁcantly more soluble in lipid
bilayers than in aqueous solution (42,43). The experiments of
Subczynski et al. (43) also suggest that amantadine is more
soluble in lipid bilayers than in bulk hydrocarbon solvent.
These experiments did not indicate the precise location of
amantadine in the lipid bilayer, or how amantadine may cross
the bilayer. An understanding of this may be particularly
timely, given that amantadine leads to undesirable side effects
within the central nervous system (44). Furthermore, the issue
of amantadine-resistant forms of the inﬂuenza A virus is of
increasing concern (45–47). During the 2005–2006 inﬂuenza
season, 92.3% of inﬂuenza A virus isolated from patients
across the United States contained the amantadine-resistant
(S31N) mutation (48). High levels of amantadine-resistant
formswere also observed in Southeast Asia andOceania (49),
as well as in Japan (50).
Molecular dynamics (MD) is methodology than can pro-
vide detailed atomic-level descriptions of systems, and is thus
a complementary method to the above series of experiments.
Indeed, there are many examples of MD simulations in the
investigation of the interactions of small molecules with lipid
membranes (51). One of the ﬁrst sets of simulations (52–55)
examined diffusion coefﬁcient solutes such as benzene in
dimyristoylphosphatidylcholine bilayers. Several groups ex-
plored the interaction of anesthetic molecules with lipid bilay-
ers (56–59), and Bemporad et al. systematically examined the
inﬂuence of various solute properties (e.g., volume or cross-
sectional area) on lipid-solute interactions (60,61), as well as on
interactions of b-blockers with membranes (62).
The potential of mean force (PMF) is free energy as a
function of a reaction coordinate. As the PMF proﬁle depends
on both enthalpic and entropic contributions, its precise cal-
culation has long been a challenge to MD, because thermo-
dynamically unfavorable regions are not well-sampled (63).
One of several methods that were developed for PMF calcu-
lations is umbrella sampling, which applies a biasing potential
to obtain better sampling in thermodynamically unfavorable
regions (64).
The PMFs have provided mechanistic insights about the
transport mechanism of ions in channels (65), in particular for
the gramicidin ion channel. Beckstein and Sansom calculated
PMFs to investigate gating mechanisms of the nicotinic ace-
tylcholine receptor (66). The PMFs were also used to under-
stand the mechanism of lipid desorption (67) and the
localization of indole rings in lipid bilayers (68). More re-
cently, the PMF of an arginine side-chain in a bilayer was
calculated (69,70), with a view to understanding the mecha-
nism of voltage-sensing in potassium channels.
Here we perform PMF calculations to calculate: 1), the
preferred location and orientation of three adamantanes
(amantadine, rimantadine, and memantine) in the bilayer; 2),
the energetic costs associated with those positions; and 3), the
preference for protonation states of these compounds at dif-
ferent locations across the bilayer. Our results support the
hypothesis that these compounds absorb into the lipid bilayer
and prefer an interfacial location.
METHODS
Each simulation system consists of one adamantine molecule (amantadine,
rimantadine, or memantine; Fig. 1), 52 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphatidylcholine (POPC) lipids in the initial setup, 1820 simple point
charge (SPC) water molecules (71), and one chloride ion. The topology of
adamantanes was obtained from the PRODRG (72) server, and charges on
atoms were recalculated at the Hartree-Fock 6-31G* level, using Spartan ’02
(Wavefunction, Irvine, CA). Charges and atom types in systems are given
explicitly in the SupplementaryMaterial (Data S1). The one-dimensional (1D)
PMF was calculated using umbrella sampling. The 1D reaction coordinate is
along the z axis, which corresponds to the bilayer normal. The umbrella po-
tential acts on the center of mass of amantadine, with an initial harmonic po-
tential of force constant of 2.4 kcal mol1 A˚2 (10 kJ mol1 A˚2). We found
that this force constant was too weak in the center of the bilayer, and thus we
systematically tested force constants up to 1194 kcal mol1 A˚2 (5000 kJ
mol1 A˚2).The starting conﬁguration for each umbrellawindowwasobtained
by placing the adamantinemolecule independently at different z coordinates, to
include 190windows each separated by awidthDz¼ 0.5 A˚. Eachwindowwas
subjected to 1000 steps of steepest-descents energy minimization to remove
bad contacts with lipid molecules, followed by 1 ns of restrained dynamics,
whereby the amantadine was held ﬁxed and the rest of the system was free to
move. Eachwindowwas ﬁrst simulated for 15 ns, with the ﬁrst 2 ns considered
an equilibration period, because trajectories afterward are statistically uncor-
related and are within an error of ;1 kcal/mol from the block average. Bad
FIGURE 1 Structureof amantadine (A), rimantadine (B), andmemantine (C).
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contacts with lipid chains were minimized out with the steepest-descents al-
gorithm. The system size is 473 473 92 A˚. The PMF proﬁle was constructed
from the biased distributions of the centers of mass of amantadine, using the
weighted-histogram analysis method with 300–500 bins, and a relative toler-
ance of 105 for the individual window offset. Statistical tests, described by
Schiferl and Wallace (73), were used to assure the convergence of free-energy
calculations, and to estimate the errors in free-energy proﬁles in the following
manner. Trajectories were divided into eight blocks of varying time lengths.
Blocks were determined to be uncorrelated by application of a Mann-Kendall
test (t¼ 0.12, n¼ 8) and a one-tailed vonNeumann test (x¼ 0.23, n¼ 8). The
Shapiro-Wilks test was used on blocks of data to determine the normality of the
distribution of mean values (W ¼ 0.7, p, 0.05, n ¼ 8).
Simulations were performed with GROMACS 3.2.1 (74) at 310 K and a
pressure of 1 bar. Additional simulations were performed with the optimized
potential for liquid simulation (OPLS) all-atom force ﬁeld (75–77), to assess the
inﬂuence of parameter choice (see the Supplementary Material, Data S1). The
Berendsen algorithm was used to couple the temperature of the system with a
coupling constant of 1 ps (78). The system pressure was coupled in semi-iso-
tropic fashion (x and y, independent of z), using the Berendsen algorithmwith a
compressibility of 13 105 bar1 and a coupling constant of 1 ps (78). Lipid
force-ﬁeld parameters were taken from Berger et al. (79). Electrostatic inter-
actions were accounted for by a particle-mesh Ewald method (80) with a real-
space cutoff of 10 A˚, a grid spacing of 0.015 A˚, and fourth-order interpolation.
The van der Waals interactions were computed with a cutoff of 10 A˚. The time
step was 2 fs. Simulations were run on a Linux cluster. Structures and ani-
mations were displayed using Visual Molecular Dynamics (81). The analysis
was performed using GROMACS and a locally written code.
RESULTS
Construction of potential of mean force
Fig. 2 shows PMFs as a function of the center of mass
derived for the adamantanes in both protonated and de-
protonated forms. The protonated forms (Fig. 2, A–C)
exhibit similarly shaped proﬁles, with a favorable free-
energy well of between 4 and 7 kcal/mol centered
around 12 A˚ from the center of the bilayer, corresponding
to the interface. The proﬁles suggest that as the protonated
forms approach the center of the bilayer, they experience a
large (11–14 kcal/mol) barrier. Whereas the PMFs for
protonated amantadine (Fig. 2 A) and rimantadine (Fig.
2 B) look similar, the PMF for protonated memantine (Fig.
2 C) has a lower barrier at the center of the bilayer. The
PMF proﬁles for deprotonated forms show that the barrier
is effectively removed, and the interaction is slightly fa-
vorable by 0.7–2.7 kcal/mol (with respect to bulk water)
in all three adamantanes (Fig. 2, D–F). Although the po-
sition of the well in the PMFs is preserved, deprotonation
reduces the depth of the well for all three compounds,
suggesting that charge interactions are important in de-
termining the extent to which the molecules interact with
the interface.
FIGURE 2 PMF for protonated amantadine (A), proton-
ated rimantadine (B), protonated memantine (C), deproto-
nated amantadine (D), deprotonated rimantadine (E), and
deprotonated memantine (F). Center of bilayer is located at
0. Error bars indicate standard error of the mean, derived
from the block-averaging procedure described in text.
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Interaction with the membrane
All three protonated forms of the adamantanes form sub-
stantial interactions with the lipid headgroups, even when
located close to the bilayer center (Fig. 3). Consistent with
previous reports on charged amino-acid side chains, the in-
teractions between compounds and lipid headgroups lead to
considerable deformation of themembrane,which also allows
water molecules to form interactions with the ammonium
moiety (Fig. 3). Such water interactions were previously ob-
served in acetic acid in lipid bilayers (62), in valproic acid
(82), and in the solvation of amino side-chains (69,70,83,84).
Based on the PMF (Fig. 2) and inspection of the trajectories,
we can observe the mode of interaction of the adamantanes
with the membrane. As they approach the headgroups of the
POPC lipids (from z¼40 A˚ to20 A˚, and from z¼ 40 A˚ to
20 A˚), they orient themselves such that the positive charge of
the ammonium group faces the negatively charged phos-
phates (Fig. 3, A, C, and E). As a result, the PMFs start to
decrease (Fig. 2). As they move closer to the interfacial re-
gion, the orientation of the adamantane ﬂips 180with respect
to the bilayer (Fig. 3, B, D, and F), and it reaches an energy-
minimum position in the PMF proﬁle. Adamantanes remain
in this orientation until they cross the center of the bilayer,
where they ﬂip such that the ammonium group orients to face
the headgroups of the other lipid leaﬂet.
In the interface region where the PMF is at a minimum, the
adamantanes appears to adopt a distinct orientation. To
quantify this, we examined the orientation of the vector of the
bond between the tricycle-decane group and the ﬁrst atom of
the substituent. Fig. 4 A shows the combined distribution (for
amantadine) of windows between z ¼ 11–14 A˚ and z ¼ 14
to 11 A˚. Similar distributions were obtained for rimanta-
dine and memantine (data not shown). The distribution
suggests an angle between 20–30, consistent with recently
reported solid-state NMR experiments (85). We also exam-
ined the radial distribution function (RDF) for the ammonium
group of amantadine with various chemical moieties, as
shown in Fig. 4, B and C. The RDFs show that for the in-
terfacial location, the predominant interaction of the ammo-
nium group is with the glycerol oxygens rather than those
of the phosphate group. However, when amantadine is situ-
ated in the center of the bilayer, interactions with different
oxygen groups are similar. Similar observations were made
for rimantadine and memantine (data not shown).
We combined the PMF proﬁles of protonated and de-
protonated forms to give the change in pKa relative to
the adamantanes in solution (pKa;amantadine ¼ 9 (86,87),
pKa;rimantadine ¼ 10.4 (87), and pKa;memantine ¼ 10.3 (88,89),
in accordance with the thermodynamic cycle shown in Fig. 5.
The free energy for deprotonation in bulk water is calculated
from the pKa values, whereas the transfer free energies are
computed directly from the PMFs. Thus, in a fashion similar to
that of previous work (77,90), we can compute change in pKa
as a function of membrane depth with respect to bulk solution.
The results for amantadine (Fig. 6 A) indicate that the pKa
is reduced by 9 pH units in the center of the bilayer, favoring
formation of the deprotonated state. The interface regions, on
the other hand, have a positive shift of;4 pH units, favoring
the protonated state in this region. Large shifts in pKa were
also evident at the center of the membrane for rimantadine
and memantine (Fig. 6, B and C). Similar scale shifts were
reported for lysine (77,90) and methyl-guanidine (90), sug-
gesting that our results are in both quantitative and qualitative
agreement. For example, MacCallum et al. (70,77) showed
that a lysine side chain would have a pKa of 2 at the center of
the bilayer, and a value of 12.5 in the region of the interface.
The pKa of lysine in aqueous solution is 10.8. Rimantadine
differs from amantadine and memantine in that the latter
exhibit positive increases in pKa in the interface region, but
rimantadine has no such change associated with it.
DISCUSSION
Implications for adamantanes as drugs
The PMF proﬁles suggest that the preferred location of
adamantanes is in the interfacial region of the lipid bilayer,
in agreement with recent experiments (41–43). The orien-
tation is such that the tricyclo-decane moiety is in contact
with the lipid alkyl chains, and the ammonium group is in
FIGURE 3 Preferred orientations near interface for amantadine (A and B),
rimantadine (C and D) and memantine (E and F).
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contact with the lipid headgroups and in particular the
glycerol oxygens. A recent NMR and MD study by Li et al.
(85) also concluded that amantadine has a distinct popula-
tion that resides in the interface region, and that the amine
headgroup also interacts with the choline and glycerol
oxygens.
Furthermore, this location is favorable with respect to bulk
water, and thus raises questions about how these compounds
interact with target proteins. For example, amantadine and
rimantadine are known to interact with (and inhibit) the M2
channel from inﬂuenza A (1,3–5) and the p7 protein from
HCV (6), whereas memantine is a known NMDA receptor
block (22,24). Two structures for the M2 channel in complex
with either amantadine (37) or rimantadine (38) were recently
reported, but with differing proposed modes of action.
Amantadine is thought to block the channel, whereas riman-
tadine is thought to interact on the exterior of the channel.
Because there is no barrier for the absorption of amantadine or
rimantadine to occupy an interfacial location (Fig. 2 B), these
results support the idea that these compounds could ﬁrst
partition into the bilayer before interacting with its target
protein (91,92). Moreover, several mutations of the M2
channel (93,94) that confer amantadine resistance to inﬂuenza
A (at residue positions 26, 27, 30, 31, or 34) are located at a
position in the bilayer that could be readily accessible from
amantadine that has already absorbed to the interface as well
as from the aqueous solution.
Although a recently determined structure supports the hy-
pothesis that amantadine sitswithin the tetramer (33,34,95,96),
it is still unclear how it would reach this site. If amantadine
does need to sit inside the pore to effect a block, some
movement of the M2 helices is likely. It is already known that
the conformation of M2 helices depends on the lipid envi-
ronment (97), suggesting a certain degree of plasticity in this
region that might allow amantadine to enter from the lipid
phase. It should also be remembered that both the x-ray and
NMR structures are of truncated peptides, and it is not known
to what extent the dynamics of the full-length protein differ
from these shorter constructs.
The proﬁles of both the protonated and deprotonated forms
of adamantanes allow for speculation about how these and
other drugs might cross the lipid bilayer. Such information is
FIGURE 4 (A) Histogram of C-N vector-bilayer normal angle taken from
simulation windows (both positive and negative with respect to center of
bilayer) 6 11–14 A˚ of protonated amantadine. (B) Representative radial
distribution function of oxygen atoms with respect to nitrogen atom of
amantadine in the interface region (z ¼ 12 A˚). (C) Radial distribution
function of oxygen atoms of phosphates and glycerol backbone with respect
to nitrogen atom of amantadine in hydrophobic core of membrane (z¼ 0 A˚).
FIGURE 5 Thermodynamic cycle used to calculate change in pKa value.
Two transfer values are calculated directly from potentials of mean force for
protonated and deprotonated forms of adamantanes. The DGbase/ acid, water
is calculated directly from pKa, as described in text.
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particularly sought after, given that 98% of all new central
nervous system candidate drugs do not cross the blood-brain
barrier efﬁciently (98). There is no barrier to absorption to the
interface region of the membrane, but there are differences in
the size of the well, depending on the protonation state of the
adamantane. For example, protonated amantadine has a well
on the order of 6.5 kcal/mol, whereas for the deprotonated
state, the well is only 2.5 kcal/mol. Similarly, protonated ri-
mantadine has a well of 5.2 kcal/mol, whereas for the de-
protonated state, the well is only 1.8 kcal/mol. Although there
is also a difference for the protonated versus deprotonated
state of memantine, the difference between them is somewhat
smaller (4.25 kcal/mol for the protonated state, versus3.7
kcal/mol for the deprotonated state).
For all three compounds, the center of the bilayer presents
a large barrier to permeation for the protonated species. The
deprotonated species at this position, on the other hand, is
slightly favorable compared with bulk (ranging from 0.8
kcal/mol for deprotonated rimantadine, to 2.7 kcal/mol for
memantine). Thus one might expect the deprotonated species
to be more likely the permeant species. The fraction of per-
meant species can be computed directly from the pKa value.
For example, with a pKa of 9, amantadine will be 97.5%
protonated (assuming a pH of 7.4 for the blood-brain barrier
in vivo). Thus, 2.5% will be deprotonated. For this species to
permeate, it must ﬁrst absorb into the favorable well, hop
over the central barrier (1 1 kcal/mol with respect to the
interface for deprotonated amantadine; Fig. 2 D) into the
favorable energy well in the second lipid leaﬂet, where it
must ﬁnally escape the second 2.5 kcal/mol energy well.
It is also of interest to compare the mode of interaction of
these molecules and those of other small molecules with lipid
bilayers. Simple alcohols are among the best-studied com-
pounds in terms of their interactions with lipid bilayers (see
Terama et al. (99) and references therein), with much of the
work focusing on the effects of alcohol on the properties of the
membrane. Patra et al. (100) analyzed the interactions of
ethanol and methanol with lipid, and concluded that ethanol
could interact with the ester groups of the lipids. Methanol
was observed not to penetrate the lipid bilayer, and was pre-
sumably too polar overall. Dickey and Faller (101) observed
that the OH group of propanol and butanol (at low concen-
trations) has greater interaction with the carbonyl groups of
dipalmitoylphosphatidylcholine bilayers than ethanol, pos-
sibly reﬂecting an increase in van der Waals interactions be-
tween alkyl chains. Mukhopadhyay et al. examined the
behavior and interaction of pentachlorophenol (PCP) with
lipid bilayers (102). They found that the hydroxyl group in-
teracted with the lipid carbonyl groups and water molecules,
whereas PCP interacted with the alkyl chains in a parallel
orientation, to optimize local packing in the dense ordered
chain region of the bilayer. Thus, although the compounds
reported in these studies and those reported here are quite
dissimilar, they illustrate that the interfacial region of the lipid
bilayer provides a suitable environment for a wide range
of chemical groups, as long as they possess a large enough
hydrophobic group (at least the size of ethanol) and a group
capable of forming hydrogen bonds with the lipid carbonyl
groups.
Limitations
It is important to note possible sources of error associatedwith
this type of calculation: 1), System-size dependence: to in-
vestigate dependence on the size of a system, we repeated the
calculation with two larger systems: one with 128 POPC
lipids, and a second with 256 POPC lipids (see the Supple-
FIGURE 6 Change in pKa (protonation of nitrogen) as a function of
membrane depth for amantadine (A), rimantadine (B), and memantine (C).
Error bars indicate standard error of the mean, according to the block-
averaging procedure described in text.
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mentary Material, Data S1). In our simulations, we estimated
the associated error to be up to 1 kcal mol1, in agreement
withAllen et al. (103), who estimated an error of up to 1.8 kcal
mol1 that could be attributed to system size; 2), We used a
nonpolarizable force ﬁeld. Allen et al. (103) examined the
inﬂuence of polarizability in detail, and concluded that a po-
larizable phospholipid could contribute a stabilizing effect of
3.6 6 0.3 kcal mol1. More recently, Vorobyov et al.
demonstrated that for an arginine analogue (the positively
charged methyl guanidinium ion), the PMF computed with a
Drude polarizable membrane reduced the barrier in the center
of the bilayer by less than 1 kcal/mol, compared with PMFs
calculated with the nonpolarizable CHARMM force-ﬁeld
(104). This was perhaps a smaller effect than might be ex-
pected (especially considering that the solvation free energy
of a charged arginine in cyclohexane is substantially under-
estimated), but can be attributed to the shielding from the lipid
hydrocarbon tails by water molecules and lipid headgroups
because of the severe deformation of the membrane when a
charged arginine is present. A similar level of membrane
deformation was observed in the presence of charged species
in this study, and thus we suggest that a similar level of error
would likely be associated with these calculations; 3), Pa-
rameter choice: the interactions between lipids and these
compounds were not explicitly validated. The underlying
assumption is that previously derived parameters are trans-
ferable to similar systems. A similar assumption was made
previously (77). To assess the inﬂuence of parameters on our
results, we repeated the amantadine calculations with a dif-
ferent parameter set (Supplementary Material, Data S1).
Those results gave remarkably similar proﬁles. Comparing
the proﬁles for amantadine (Fig. 2, A and D) with the OPLS-
AA force-ﬁeld parameter set (Fig. S6, Data S1) shows that the
error associated with the choice of parameter set is on the
order of 0.5 kcal/mol.
CONCLUSIONS
We were able to demonstrate the preferred location of ada-
mantane derivatives within a lipid bilayer. Furthermore, we
showed that amantadine and rimantadine are likely to be
protonated at this interfacial location in POPC lipids. Mem-
antine, on the other hand, has only a slight preference for the
protonated state at this position. These aspects are likely to be
important for an understanding of how these compounds
reach their targets within the cell.
Our results also suggest that the membrane-permeant spe-
cies in all cases is likely to be the deprotonated form.Whether
that deprotonation step proceeds in the bulk solution or after
initial absorption into the interface region remains to be seen.
The complexity of proﬁles highlights the dangers of trying
to comparemembrane afﬁnity with drug permeability (60,105),
and demonstrates that the membrane cannot be treated as a
simple continuum slab. A similar conclusion was reached
through recent work on charged amino-acid side chains in
membranes (106). Such considerations will be important for a
better understanding of drug designs.
SUPPLEMENTARY MATERIAL
To view all of the supplemental ﬁles associated with this
article, visit www.biophysj.org.
We thank our colleagues for useful discussions, and in particular, Ranjit
Vijayan, Mark Sansom, Chze Ling Wee, and Nicole Zitzmann.
We thank the Wellcome Trust for support. C.F.C. thanks the Overseas
Research Scheme for support, and the National Grid Service for computer
time. P.C.B. is a Research Councils of United Kingdom Fellow.
REFERENCES
1. Pinto, L. H., and R. A. Lamb. 2007. Controlling inﬂuenza virus
replication by inhibiting its proton channel. Mol. Biosyst. 3:18–23.
2. Blanchet, P. J., L. V. Metman, and T. N. Chase. 2003. Renaissance of
amantadine in the treatment of Parkinson’s disease. Adv. Neurol.
91:251–257.
3. Davies, W. L., R. R. Grunert, R. F. Haff, J. W. McGahen, E. M.
Neumayer, M. Paulshock, J. C. Watts, T. R. Wood, E. C. Herrman,
and C. E. Hoffman. 1964. Antiviral activity of 1-adamantadine
(amantadine). Science. 144:862–863.
4. Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985.
The molecular basis of the speciﬁc anti-inﬂuenza action of amanta-
dine. EMBO J. 4:3021–3024.
5. Pinto, L. H., L. J. Holsinger, and R. A. Lamb. 1992. Inﬂuenza virus
M2 protein has ion channel activity. Cell. 69:517–528.
6. Grifﬁn, S. D., L. P. Beales, D. S. Clarke, O. Worsfold, S. D. Evans, J.
Jaeger, M. P. Harris, and D. J. Rowlands. 2003. The p7 protein of
hepatitis C virus forms an ion channel that is blocked by the antiviral
drug, amantadine. FEBS Lett. 535:34–38.
7. Steinmann, E., T. Whitﬁeld, S. Kallis, R. A. Dwek, N. Zitzmann, T.
Pietschmann, and R. Bartenschlager. 2007. Antiviral effects of aman-
tadine and iminosugar derivatives against hepatitis C virus. Hepatology.
46:330–338.
8. Riley, T. R., and M. R. Taheri. 2007. Long-term treatment with the
combination of amantadine and ribavirin in hepatitis C nonre-
sponders. A case series. Dig. Dis. Sci. 52:3418–3422.
9. Brillanti, S., F. Levantesi, L. Masi, M. Foli, and L. Bolondi. 2000.
Triple antiviral therapy as a new option for patients with interferon
nonresponsive chronic hepatitis C. Hepatology. 32:630–634.
10. Deltenre, P., J. Henrion, V. Canva, S. Dharancy, F. Texier, A. Louvet,
S. De Maeght, J. C. Paris, and P. Mathurin. 2004. Evaluation of aman-
tadine in chronic hepatitis C: a meta-analysis. J. Hepatol. 41:462–
473.
11. Mangia, A., G. Leandro, B. Helbling, E. L. Renner, M. Tabone, L.
Sidoli, S. Caronia, G. R. Foster, S. Zeuzem, T. Berg, V. Di Marco, N.
Cino, and A. Andriulli. 2004. Combination therapy with amantadine
and interferon in naive patients with chronic hepatitis C: meta-
analysis of individual patient data from six clinical trials. J. Hepatol.
40:478–483.
12. Mangia, A., G. L. Ricci, M. Persico, N. Minerva, V. Carretta, D.
Bacca, M. Cela, M. Piattelli, M. Annese, G. Maio, D. Conte, V.
Guadagnino, V. Pazienza, D. Festi, F. Spirito, and A. Andriulli. 2005.
A randomized controlled trial of pegylated interferon alpha-2a
(40KD) or interferon alpha-2a plus ribavirin and amantadine vs
interferon alpha-2a and ribavirin in treatment-naive patients with
chronic hepatitis C. J. Viral Hepat. 12:292–299.
13. Berg, T., B. Kronenberger, H. Hinrichsen, T. Gerlach, P. Buggisch, E.
Herrmann, U. Spengler, T. Goeser, S. Nasser, K. Wursthorn, G. R.
Pape, U. Hopf, and S. Zeuzem. 2003. Triple therapy with amantadine
Dynamics of Adamantanes in a Bilayer 5633
Biophysical Journal 95(12) 5627–5636
in treatment-naive patients with chronic hepatitis C: a placebo-
controlled trial. Hepatology. 37:1359–1367.
14. Ciancio, A., A. Picciotto, C. Giordanino, A. Smedile, M. Tabone, A.
Manca, G. Marenco, P. Garbagnoli, M. Andreoni, G. Cariti, G.
Calleri, M. Sartori, S. Cusumano, A. Grasso, R. Rizzi, M. Gallo, M.
Basso, M. Anselmo, G. Percario, G. Ciccone, M. Rizzetto, and G.
Saracco. 2006. A randomized trial of pegylated-interferon-alpha2a
plus ribavirin with or without amantadine in the re-treatment of
patients with chronic hepatitis C not responding to standard interferon
and ribavirin. Aliment. Pharmacol. Ther. 24:1079–1086.
15. Craxi, A., and O. Lo Lacono. 2001. Amantadine for chronic hepatitis
C: a magic bullet or yet another dead duck? J. Hepatol. 35:527–530.
16. Khalili, M., C. Denham, and R. Perrillo. 2000. Interferon and ribavirin
versus interferon and amantadine in interferon nonresponders with
chronic hepatitis C. Am. J. Gastroenterol. 95:1284–1289.
17. Thuluvath, P. J., A. Maheshwari, J. Mehdi, K. D. Fairbanks, L. L.
Wu, L. G. Gelrud, M. J. Ryan, F. A. Anania, I. F. Lobis, and M.
Black. 2004. Randomised, double blind, placebo controlled trial of
interferon, ribavirin, and amantadine versus interferon, ribavirin, and
placebo in treatment naive patients with chronic hepatitis C. Gut.
53:130–135.
18. Kilpatrick, G. J., and G. S. Tilbrook. 2002. Memantine. Merz. Curr.
Opin. Investig. Drugs. 3:798–806.
19. Oxford, J. S., and A. Galbraith. 1980. Antiviral activity of amanta-
dine: a review of laboratory and clinical data. Pharmacol. Ther.
11:181–262.
20. Jackish, R., T. Link, B. Neufang, and R. Koch. 1992. Studies on the
mechanism of action of the antiparkinsonian drugs memantine and
amantadine: no evidence for direct dopaminergic or antimuscurinic
properties. Arch. Int. Pharmacodyn. Ther. 320:21–42.
21. Danielczyk, W. 1995. Twenty-ﬁve years of amantadine therapy in
Parkinson’s disease. J. Neural Transm. Suppl. 46:399–405.
22. Alisky, J. M. 2007. Successful treatment of Parkinson’s disease with
memantine. South. Med. J. 100:617.
23. Eldefrawi, A. T., E. R. Miller, D. L. Murphy, and M. E. Eldefrawi.
1982. [3H] Phencyclidine interactions with the nicotinic acetylcholine
receptor channel and its inhibition by psychotropic, antipsychotic,
opiate, antidepressant, antibiotic, antiviral and antiarrhythmic drugs.
Mol. Pharm. 22:72–81.
24. Lipton, S. A. 2006. Paradigm shift in neuroprotection by NMDA
receptor blockade: memantine and beyond. Nat. Rev. Drug Discov.
5:160–170.
25. Jensen, A. A., B. Frølund, T. Liljefors, and P. Krogsgaard-Larsen.
2005. Neuronal nicotinic acetylcholine receptors: structural revela-
tions, target identiﬁcations and therapeutic inspirations. J. Med.
Chem. 48:4705–4745.
26. Francis, P. T. 2008. Glutamatergic approaches to the treatment of
cognitive and behavioural symptoms of Alzheimer’s disease. Neuro-
degener. Dis. 5:241–243.
27. Cheung, W., L. Guo, and M. F. Cordeiro. 2008. Neuroprotection in
glaucoma: drug-based approaches. Optom. Vis. Sci. 85:406–416.
28. Freisleben, H. J., G. Waltinger, W. Schatton, and G. Zimmer. 1989.
Inﬂuences of tromantadine and nonoxinol 9 on the stability of red cell
membrane. Arzneim. Forsch. Drug Res. 39:1202–1205.
29. Phonphok, Y., and K. S. Rosenthal. 1991. Stabilization of clathrin
coated vesicles by amantadine, tromantadine and other hydrophobic
amines. FEBS Lett. 281:188–190.
30. Jain, M. K., N. Yen-Min Wu, T. K. Morgan, M. S. Briggs, and R. K. J.
Murray. 1976. Phase transition in a lipid bilayer. II. Inﬂuence of
amantadine derivatives. Chem. Phys. Lipids. 17:71–78.
31. Sansom, M. S. P., and I. D. Kerr. 1993. Inﬂuenza virus M2 protein: a
molecular modelling study of the ion channel. Protein Eng. 6:65–74.
32. Pinto, L. H., and R. A. Lamb. 1995. Understanding the mechanism of
action of the anti-inﬂuenza virus drug amantadine. Trends Microbiol.
3:271.
33. Astrahan, P., I. Kass, M. A. Cooper, and I. T. Arkin. 2004. A novel
method of resistance for inﬂuenza against a channel-blocking antiviral
drug. Proteins. 55:251–257.
34. Hu, J., T. Asbury, S. Achuthan, C. Li, R. Bertram, J. R. Quine, R. Fu,
and T. A. Cross. 2007. Backbone structure of the amantadine-blocked
trans-membrane domain M2 proton channel from inﬂuenza A virus.
Biophys. J. 92:4335–4343.
35. Salom, D., B. R. Hill, J. D. Lear, and W. F. DeGrado. 2000. pH-
Dependent tetramerization and amantadine binding of the transmem-
brane helix of M2 from the inﬂuenza A virus. Biochemistry.
39:14160–14170.
36. Wang, C., K. Takeuchi, L. H. Pinto, and R. A. Lamb. 1993. Ion
channel activity of inﬂuenza A virus M2 protein: characterization of
the amantadine block. J. Virol. 67:5585–5594.
37. Stouffer, A. L., R. Acharya, D. Salom, A. S. Levine, L. Di Costanzo,
C. S. Soto, V. Tereshko, V. Nanda, S. Stayrook, and W. F. DeGrado.
2008. Structural basis for the function and inhibition of an inﬂuenza
virus proton channel. Nature. 451:596–599.
38. Schnell, J. R., and J. J. Chou. 2008. Structure and mechanism of the
M2 proton channel of inﬂuenza A virus. Nature. 451:591–595.
39. Cady, S. D., and M. Hong. 2008. Amantadine-induced conforma-
tional and dynamical changes of the inﬂuenza M2 transmembrane
proton channel. Proc. Natl. Acad. Sci. USA. 105:1483–1488.
40. Balaz, S. 2000. Lipophilicity in trans-bilayer transport and subcellular
pharmacokinetics. Perspect. Drug Discov. Des. 19:157–177.
41. Duff, K. C., P. J. Gilchrist, A. M. Saxena, and J. P. Bradshaw. 1994.
Neutron diffraction reveals the site of amantadine blockade of the
inﬂuenza A M2 ion channels. Virology. 202:287–293.
42. Wang, J., J. R. Schnell, and J. J. Chou. 2004. Amantadine partition
and localization in phospholipid membrane: a solution NMR study.
Biochem. Biophys. Res. Commun. 324:212–217.
43. Subczynski, W. K., J. Wojas, V. Pezeshk, and A. Pezeshk. 1998.
Partitioning and localization of spin-labeled amantadine in lipid
bilayers: an EPR study. J. Pharm. Sci. 87:1249–1254.
44. Skehel, J. J. 1992. Inﬂuenza virus. Amantadine blocks the channel.
Nature. 358:110–111.
45. Bright, R. A., M.-J. Medina, X. Xu, G. Perez-Oronoz, T. R. Wallis,
X. M. Davis, L. Povinelli, N. J. Cox, and A. I. Klimov. 2005. Incidence
of adamantane resistance among inﬂuenza A (H3N2) viruses isolated
worldwide from 1994–2005: a cause for concern. Lancet. 366:1175–
1181.
46. Deyde, V. M., X. Xu, R. A. Bright, M. Shaw, C. B. Smith, Y. Zhang,
Y. Shu, L. V. Gubareva, N. J. Cox, and A. I. Klimov. 2007.
Surveillance of resistance to adamantanes among inﬂuenza A
(H3N2) and A (H1N1) viruses isolated worldwide. J. Infect. Dis.
196:249–257.
47. de Clercq, E., and J. Neyts. 2007. Avian inﬂuenza A (H5N1)
infection: targets and strategies for chemotherapeutic intervention.
Trends Pharmacol. Sci. 28:280–285.
48. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006.
Adamantane resistance among inﬂuenza A viruses isolated early
during the 2005–2006 inﬂuenza season in the United States. JAMA.
295:891–894.
49. Barr, I.G.,A.C.Hurt,N.Deed,P. Ianello,C.Tomasov, andN.Komadina.
2007. The emergence of adamantane resistance in inﬂuenza A (H1)
viruses in Australia and regionally in 2006. Antiviral Res. 75:173–176.
50. Saito, R., D. Li, and H. Suzuki. 2007. Amantadine-resistant inﬂuenza
A (H3N2) virus in Japan, 2005–2006. N. Engl. J. Med. 356:312–313.
51. Pohorille, A., M. H. New, K. Schweighofer, and M. A. Wilson. 1999.
Insights from computer simulations into the interaction of small
molecules with lipid bilayers. Curr. Top. Membr. Trans. 48:49–76.
52. Bassolino-Klimas, D., H. E. Alper, and T. R. Stouch. 1993. Solute
diffusion in lipid bilayer membranes: an atomic level study by
molecular dynamics simulation. Biochemistry. 32:12624–12637.
5634 Chew et al.
Biophysical Journal 95(12) 5627–5636
53. Bassolino-Klimas, D., H. E. Alper, and T. R. Stouch. 1995. Mech-
anism of solute diffusion through lipid bilayer membranes by molec-
ular dynamics simulation. J. Am. Chem. Soc. 117:4118–4129.
54. Alper, H. E., and T. R. Stouch. 1995. Orientation and diffusion of a
drug analog in biomembranes—molecular dynamics simulations.
J. Phys. Chem. 99:5724–5731.
55. Stouch, T. R., H. E. Alper, and D. Bassolino. 1995. Simulations of
drug diffusion in biomembranes. ACS Symp. Ser. 589:127–138.
56. Cascales, L. J. J., H. J. G. Cifre, and G. J. de laTorre. 1998.
Anaesthetic mechanism on a model biological membrane: a molecular
dynamics simulation study. J. Phys. Chem. B. 102:625–631.
57. Koubi, L., M. Tarek, S. Bandyopadhyay, M. L. Klein, and D. Scharf.
2001. Membrane structural perturbations caused by anesthetics and
nonimmobilizers: a molecular dynamics investigation. Biophys. J.
81:3339–3345.
58. Vemparala, S., L. Saiz, R. G. Eckenhoff, and M. L. Klein. 2006.
Partitioning of anesthetics into a lipid bilayer and their interaction
with membrane-bound peptide bundles. Biophys. J. 91:2815–2825.
59. Ho¨gberg, C. J., A. Maliniak, and A. P. Lyubartsev. 2007. Dynamical
and structural properties of charged and uncharged lidocaine in a lipid
bilayer. Biophys. Chem. 125:416–424.
60. Bemporad, D., C. Luttmann, and J. W. Essex. 2004. Computer
simulation of small molecule permeation across a lipid bilayer:
dependence on bilayer properties and solute volume, size and cross-
sectional area. Biophys. J. 87:1–13.
61. Bemporad, D., J. W. Essex, and C. Luttmann. 2004. Permeation of
small molecules through a lipid bilayer: a computer simulation study.
J. Phys. Chem. B. 108:4875–4884.
62. Bemporad, D., C. Luttmann, and J. W. Essex. 2005. Behaviour of
small solutes and large drugs in a lipid bilayer from computer
simulations. Biochim. Biophys. Acta. 1718:1–21.
63. King, P. M. 1993. Free energy via molecular simulation: a primer. In
Computer Simulation of Biomolecular Systems. W. F. Van Gunste-
ren, P. K. Weiner, and A. J. Wilkinson, editors. ESCOM, Leiden.
267–314.
64. Torrie, G. M., and J. P. Valleau. 1977. Nonphysical sampling
distributions in Monte Carlo free-energy estimation: umbrella sam-
pling. J. Comput. Phys. 23:187–199.
65. Allen, T. W., O. S. Andersen, and B. Roux. 2006. Molecular
dynamics—potential of mean force calculations as a tool for under-
standing ion permeation and selectivity in narrow channels. Biophys.
Chem. 124:251–267.
66. Beckstein, O., and M. S. P. Sansom. 2006. A hydrophobic gate in an
ion channel: the closed state of the nicotinic acetylcholine receptor.
Phys. Biol. 3:147–159.
67. Tieleman, D. P., and S.-J. Marrink. 2006. Lipids out of equilibrium:
energetics of desorption and pore mediated ﬂip-ﬂop. J. Am. Chem.
Soc. 128:12462–12467.
68. Norman, K. E., and H.Nymeyer. 2006. Indole localization in lipid mem-
branes revealed by molecular simulation. Biophys. J. 91:2046–2054.
69. Dorairaj, S., and T. W. Allen. 2007. On the thermodynamic stability
of a charged arginine side chain in a transmembrane helix. Proc. Natl.
Acad. Sci. USA. 104:4943–4948.
70. MacCallum, J. L., W. F. Bennett, and D. P. Tieleman. 2007.
Partitioning of amino acid side chains into lipid bilayers: results
from computer simulations and comparison to experiment. J. Gen.
Physiol. 129:6206–6210.
71. Hermans, J., H. J. C. Berendsen, W. F. van Gunsteren, and J. P. M.
Postma. 1984. A consistent empirical potential for water-protein
interactions. Biopolymers. 23:1513–1518.
72. Schuettelkopf, A. W., and D. M. F. van Aalten. 2004. PRODRG—a
tool for high-throughput crystallography of protein-ligand complexes.
Acta Crystallogr. D Biol. Crystallogr. 60:1355–1363.
73. Schiferl, S. K., and D. C. Wallace. 1985. Statistical errors in
molecular dynamics averages. J. Chem. Phys. 83:5203–5209.
74. van der Spoel, D., E. Lindahl, B. Hess, G. Groenhof, A. E. Mark, and
H. J. C. Berendsen. 2005. GROMACS: fast, ﬂexible and free. J. Com-
put. Chem. 26:1701–1718.
75. Jorgensen, W. L., D. S. Maxwell, and J. Tirado-Rives. 1996. Devel-
opment and testing of the OPLS all-atom force ﬁeld on conforma-
tional energetics and properties of organic liquids. J. Am. Chem. Soc.
118:11225–11236.
76. Coll, E. P., C. Kandt, D. A. Bird, A. L. Samuels, and D. P. Tieleman.
2007. The distribution and conformation of very long-chain plant wax
components in a lipid bilayer. J. Phys. Chem. B. 111:8702–8704.
77. MacCallum, J. L., W. F. D. Bennett, and D. P. Tieleman. 2008.
Distribution of amino acids in a lipid bilayer from computer simu-
lations. Biophys. J. 94:3393–3404.
78. Berendsen, H. J. C., J. P. M. Postma, W. F. van Gunsteren, A.
DiNola, and J. R. Haak. 1984. Molecular dynamics with coupling to
an external bath. J. Chem. Phys. 81:3684–3690.
79. Berger, O., O. Edholm, and F. Jahnig. 1997. Molecular dynamics
simulations of a ﬂuid bilayer of dipalmitoylphosphatidycholine at full
hydration, constant pressure and constant temperature. Biophys. J.
72:2002–2013.
80. Darden, T., D. York, and L. Pedersen. 1993. Particle mesh Ewald—an
N.log(N) method for Ewald sums in large systems. J. Chem. Phys.
98:10089–10092.
81. Humphrey, W., A. Dalke, and K. Schulten. 1996. VMD—visual
molecular dynamics. J. Mol. Graph. 14:33–38.
82. Ulander, J., and A. D. J. Haymet. 2003. Permeation across hydrated
dppc lipid bilayers: simulation of the titrable amphophilic drug
valproic acid. Biophys. J. 85:3475–3484.
83. Freites, J. A., D. J. Tobias, G. von Heijne, and S. H. White. 2005.
Interface connections of a transmembrane voltage sensor. Proc. Natl.
Acad. Sci. USA. 102:15059–15064.
84. Johansson, A. C., and E. Lindahl. 2006. Amino-acid solvation
structure in transmembrane helices from molecular dynamics simula-
tions. Biophys. J. 91:4450–4463.
85. Li, C., M. Yi, J. Hu, H.-X. Zhou, and T. A. Cross. 2008. Solid-state
NMR and MD simulations of the antiviral drug amantadine solubi-
lized in DMPC bilayers. Biophys. J. 94:1295–1302.
86. Bleidner, W. E., J. B. Harmon, W. E. Hewes, T. E. Lynes, and E. C.
Hermann. 1965. Absorption, distribution and excretion of amantadine
hydrochloride. J. Pharmacol. Exp. Ther. 150:484–490.
87. Spector, R. 1988. Transport of amantadine and rimantadine through
the blood-brain barrier. J. Pharmacol. Exp. Ther. 244:516–519.
88. Wesemann, W., K. H. Sontag, and J. Maj. 1983. Pharmacodynamics
and pharmacokinetics of memantine. Arzneim. Forsch. Drug Res.
33:1122–1134.
89. Freudenthaler, S., I. Meineke, F. H. Schreeb, E. Boakye, U. Gundert-
Remy, andC.H. Gleiter. 1998. Inﬂuence of urine pH and urinary ﬂow on
the renal excretion of memantine. Br. J. Clin. Pharmacol. 46:541–546.
90. Li, L., I. Vorobyov, A. D. MacKerell Jr., and T. W. Allen. 2008. Is
arginine charged in a membrane? Biophys. J. 94:L11–L13.
91. Mason, R. P., D. G. Rhodes, and L. G. Herbette. 1991. Reevaluating
equilibrium and kinetic binding parameters for lipophilic drugs based
on a structural model for drug interaction with biological membranes.
J. Med. Chem. 34:869–877.
92. Kolocouris, A., R. K. Hansen, and R. W. Broadhurst. 2004. Interac-
tion between an amantadine analogue and the transmembrane portion
of the inﬂuenza A M2 protein in liposomes probed by 1H NMR
spectroscopy of the ligand. J. Med. Chem. 47:4975–4978.
93. Hay, A. J., M. C. Zambon, A. J. Wolstenholme, J. J. Skehel, and
M. H. Smith. 1986. Molecular basis of resistance of inﬂuenza A
viruses to amantadine. J. Antimicrob. Chemother. 8(Suppl. B):19–29.
94. Belshe, R. B., M. H. Smith, C. B. Hall, R. Betts, and A. J. Hay. 1988.
Genetic basis of resistance to rimantadine emerging during treatment
of inﬂuenza virus infection. J. Virol. 62:1508–1512.
95. Reference deleted in proof.
Dynamics of Adamantanes in a Bilayer 5635
Biophysical Journal 95(12) 5627–5636
96. Stouffer, A. L., V. Nanda, J. D. Lear, and W. F. DeGrado. 2005.
Sequence determinants of a transmembrane proton channel: an
inverse relationship between stability and function. J. Mol. Biol.
347:169–179.
97. Duong-Ly, K. C., V. Nanda, W. F. DeGrado, and K. P. Howard.
2005. The conformation of the pore region of the M2 proton
channel depends on the lipid bilayer environment. Protein Sci.
14:856–861.
98. Terasaki, T., and W. M. Pardridge. 2000. Targeted drug delivery to
the brain (blood-brain barrier, efﬂux, endothelium, biological trans-
port). J. Drug Target. 8:353–355.
99. Terama, E., O. H. S. Ollila, E. Salonen, A. C. Rowat, C. Trandum,
P. Westh, M. Patra, M. Karttunen, and I. Vattulainen. 2008.
Inﬂuence of ethanol on lipid membranes: from lateral pressure
proﬁles to dynamics and partitioning. J. Phys. Chem. B. 112:4131–
4139.
100. Patra, M., E. Salonen, E. Terama, I. Vattulainen, R. Faller, B. W. Lee,
J. Holopainen, and M. Karttunen. 2006. Under the inﬂuence of
alcohol: the effect of ethanol and methanol on lipid bilayers. Biophys.
J. 90:1121–1135.
101. Dickey, A. N., and R. Faller. 2007. How alcohol chain-length and
concentration modulate hydrogen bond formation in a lipid bilayer.
Biophys. J. 92:2366–2376.
102. Mukhopadhyay, P., H. J. Vogel, and D. P. Tieleman. 2004. Distri-
bution of pentachlorophenol in phospholipid bilayers: a molecular
dynamics study. Biophys. J. 86:337–345.
103. Allen, T. W., O. S. Andersen, and B. Roux. 2006. Ion permeation
through a narrow channel: using gramicidin to ascertain all-atom
molecular dynamics potential of mean force methodology and bio-
molecular force-ﬁelds. Biophys. J. 90:3447–3468.
104. Vorobyov, I., L. Li, and T. W. Allen. 2008. Assessing atomistic and
coarse-grained force ﬁelds for protein-lipid interactions: the formida-
ble challenge of an ionizable side chain in a membrane. J. Phys.
Chem. B. 112:9588–9602.
105. Thomae, A. V., T. Koch, C. Panse, H. Wunderli-Allenspach, and
S. D. Kra¨mer. 2007. Comparing the lipid membrane afﬁnity and
permeation of drug-like acids: the intriguing effects of cholesterol
and charged lipids. Pharm. Res. 24:1457–1472.
106. Allen, T. W. 2007. Modeling charged side-chains in lipid membranes.
J. Gen. Physiol. 130:237–240.
5636 Chew et al.
Biophysical Journal 95(12) 5627–5636
